Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study

American Journal of Hematology

Volumn 85, Issue 12, 2010, Pages 921-925

  Paul, Carle ^a,b   Sans, Beatrix ^b   Suarez, Felipe ^c   Casassus, Philippe ^d   Barete, Stéphane ^e   Lanternier, Fanny ^f   Grandpeix Guyodo, Catherine ^c   Dubreuil, Patrice ^g,h,j,k   Palmérini, Fabienne ^g,h,j,k   Mansfield, Colin D ^h   Gineste, Paul ^h   Moussy, Alain ^h   Hermine, Olivier ^c,h,i   Lortholary, Olivier ^f  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b CHU PURPAN   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d AVICENNE HOSPITAL   (France)

^e HÔPITAL TENON   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g INSERM   (France)

^h AB Science   (France)

ⁱ CNRS   (France)

^j INSTITUT PAOLI CALMETTES   (France)

^k AIX MARSEILLE UNIVERSITY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MASITINIB; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ADULT; AGRANULOCYTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS MASTOCYTOSIS; DEPRESSION; DISABILITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FLUSHING; GENE MUTATION; GENERAL CONDITION IMPROVEMENT; HUMAN; MALE; MAST CELL; MASTOCYTOSIS; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; STATISTICAL SIGNIFICANCE; SYSTEMIC MASTOCYTOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HUMANS; MALE; MASTOCYTOSIS, CUTANEOUS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MUTATION, MISSENSE; THIAZOLES; TREATMENT OUTCOME;

EID: 78649504351     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21894     Document Type: Article

References (22)

1. Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 2006; 19: 595-615.
2. Hermine O, Lortholary O, Leventhal PS, et al. Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS ONE 2008; 3(5): e2266.doi: 10.1371/journal.pone. 0002266.
3. Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: OUTCOME analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009; 84: 790-794.
4. Gotlib J. On being metachromatic: mystique and misunderstanding in mastocytosis. Am J Hematol 2009; 84: 779-781.
5. Reber L, DaSilva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2008; 533: 327-340.
6. Jensen BM, Akin C, Gilfillan AM. Pharmacological targeting of the KIT growth factor receptor: A therapeutic consideration for mast cell disorders. Br J Pharmacol 2008; 154: 1572-1582.
7. Orfao A, Garcia-Montero AC, Sanchez L, et al. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007; 138: 12-30.
8. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366-2372.
9. Lanternier F, Cohen-Akenine A, Palmerini F, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE 2008; 3: e1906.doi:10.1371/journal.pone.0001906.
10. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE 2009; 4: e7258.doi:10.1371/journal.pone.0007258
11. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916.
12. Fernandez A, Sanguino A, Peng Z, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 2007; 117: 4044-4054.
13. Atallah E, Durand JB, Kantarjia H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110: 1233-1237.
14. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 2006; 6: 218-230.
15. Hamilton M. A rating scale for depression. J Neurol Neurosur Ps 1960; 23: 56-62.
16. Hedlund JL, Vieweg BW. The Hamilton Rating Scale for Depression: A comprehensive review. J Oper Psychiatry 1979; 10: 149-161.
17. Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
18. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001; 98: 2200-2209.
19. Van Glabbeke M, Verweij J, Casali PG, et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 2006; 42: 2277-2285.
20. Bartolovic K, Balabanov S, Hartmann U, et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 2004; 103: 523-529.
21. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial. Cancer 2006; 107: 345-351.
22. Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009; 33: 1481-1484.